🚀 VC round data is live in beta, check it out!
QuidelOrtho Valuation Multiples
Discover revenue and EBITDA valuation multiples for QuidelOrtho and similar public comparables like SKAN Group, Sinocare, Nolato, Oxford Nanopore Technologies and more.
QuidelOrtho Overview
About QuidelOrtho
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Founded
1987
HQ
Employees
6.5K
Website
Financials (LTM)
EV
$4B
QuidelOrtho Financials
QuidelOrtho reported last 12-month revenue of $3B and EBITDA of $608M.
In the same LTM period, QuidelOrtho generated $1B in gross profit, $608M in EBITDA, and $145M in net income.
Revenue (LTM)
QuidelOrtho P&L
In the most recent fiscal year, QuidelOrtho reported revenue of $3B and EBITDA of $597M.
QuidelOrtho expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 49% | XXX | 47% | XXX | XXX | XXX |
| EBITDA | $608M | XXX | $597M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $145M | XXX | $144M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | — | — | $2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
QuidelOrtho Stock Performance
QuidelOrtho has current market cap of $1B, and enterprise value of $4B.
Market Cap Evolution
QuidelOrtho's stock price is $21.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $1B | 0.0% | XXX | XXX | XXX | $2.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialQuidelOrtho Valuation Multiples
QuidelOrtho trades at 1.5x EV/Revenue multiple, and 6.8x EV/EBITDA.
EV / Revenue (LTM)
QuidelOrtho Financial Valuation Multiples
As of March 31, 2026, QuidelOrtho has market cap of $1B and EV of $4B.
Equity research analysts estimate QuidelOrtho's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
QuidelOrtho has a P/E ratio of 10.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 6.8x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBIT | 10.8x | XXX | 11.0x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | 3.2x | XXX | XXX | XXX |
| P/E | 10.0x | XXX | 10.0x | XXX | XXX | XXX |
| EV/FCF | (183.5x) | XXX | (53.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified QuidelOrtho Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
QuidelOrtho Margins & Growth Rates
QuidelOrtho's revenue in the last 12 month grew by 2%.
QuidelOrtho's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
QuidelOrtho's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
QuidelOrtho's rule of X is 27% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
QuidelOrtho Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 27% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
QuidelOrtho Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SKAN Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinocare | XXX | XXX | XXX | XXX | XXX | XXX |
| Nolato | XXX | XXX | XXX | XXX | XXX | XXX |
| Oxford Nanopore Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Enovis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
QuidelOrtho M&A Activity
QuidelOrtho acquired XXX companies to date.
Last acquisition by QuidelOrtho was on XXXXXXXX, XXXXX. QuidelOrtho acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by QuidelOrtho
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialQuidelOrtho Investment Activity
QuidelOrtho invested in XXX companies to date.
QuidelOrtho made its latest investment on XXXXXXXX, XXXXX. QuidelOrtho invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by QuidelOrtho
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout QuidelOrtho
| When was QuidelOrtho founded? | QuidelOrtho was founded in 1987. |
| Where is QuidelOrtho headquartered? | QuidelOrtho is headquartered in United States. |
| How many employees does QuidelOrtho have? | As of today, QuidelOrtho has over 6K employees. |
| Who is the CEO of QuidelOrtho? | QuidelOrtho's CEO is Brian J. Blaser. |
| Is QuidelOrtho publicly listed? | Yes, QuidelOrtho is a public company listed on Nasdaq. |
| What is the stock symbol of QuidelOrtho? | QuidelOrtho trades under QDEL ticker. |
| When did QuidelOrtho go public? | QuidelOrtho went public in 1981. |
| Who are competitors of QuidelOrtho? | QuidelOrtho main competitors are SKAN Group, Sinocare, Nolato, Oxford Nanopore Technologies. |
| What is the current market cap of QuidelOrtho? | QuidelOrtho's current market cap is $1B. |
| What is the current revenue of QuidelOrtho? | QuidelOrtho's last 12 months revenue is $3B. |
| What is the current revenue growth of QuidelOrtho? | QuidelOrtho revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of QuidelOrtho? | Current revenue multiple of QuidelOrtho is 1.5x. |
| Is QuidelOrtho profitable? | Yes, QuidelOrtho is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of QuidelOrtho? | QuidelOrtho's last 12 months EBITDA is $608M. |
| What is QuidelOrtho's EBITDA margin? | QuidelOrtho's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of QuidelOrtho? | Current EBITDA multiple of QuidelOrtho is 6.8x. |
| What is the current FCF of QuidelOrtho? | QuidelOrtho's last 12 months FCF is ($22M). |
| What is QuidelOrtho's FCF margin? | QuidelOrtho's last 12 months FCF margin is (1%). |
| What is the current EV/FCF multiple of QuidelOrtho? | Current FCF multiple of QuidelOrtho is (183.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.